Show pagesourceBacklinksCite current pageExport to PDFBack to top Share via Share via... Twitter LinkedIn Facebook Pinterest Telegram WhatsApp Yammer Reddit TeamsRecent ChangesSend via e-MailPrintPermalink × Toxic leadership Identification and Management of Late toxicities after Radiotherapy for Vulvar CancerReal-world evidence on biologic use in paediatric asthma: there but not there yet?Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute StudiesRole of Toxic Leaders in Shaping the Healthcare Providers' EngagementA phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisExpanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategiesA phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)Prospective assessment of MR-guided single-fraction stereotactic ablative radiotherapy for peripheral lung metastases: dosimetric and clinical outcomes toxic_leadership.txt Last modified: 2025/06/17 20:38by administrador